Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).
Angel Qin(University of Michigan), Yifan Zhai(Unknown), Robert Winkler, Vakessa Hammock, Riccardo Bombelli(Pharmaxis (Australia)), Zhicong He(Pharmaxis (Australia)), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Cunlin Wang, Jacob Sands(Harvard University), Zhiyan Liang(East China University of Science and Technology), Nisha Mohindra(Fox Chase Cancer Center), Gregory P. Kalemkerian(University of Michigan), Ming Lu(Henan Medical University), Dajun Yang(Ascendis Pharma (Denmark)), Tommy Fu, Yang Xu(Jilin University), Jennifer W. Carlisle(Emory University)
Cited by 5
Related Papers
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|484